NG Bio, an early-stage longevity investor and venture builder that extends health span. We address the harmful immune responses, such as inflammation, that cause or exacerbate many of the major human diseases. As scientists continue to unlock the secrets to the drivers of inflammation, NG Bio is creating the next generation of medicines and diagnostics in the breakthrough areas of cure, personalisation, regeneration, and women’s health. We partner with world leading entrepreneurs, research institutions and academic institutions across the globe to realise our vision of life with control over chronic diseases. Creating the next wave of medicines for autoimmunity and inflammation means we are focused on curative medicines, personalised medicines, tissue regeneration and repair, and women's health. Our core operations span Europe, but we appreciate that life changing ideas are not geographically restricted and consider opportunities where they arise. Over the last year, our portfolio has grown to include therapeutics for conditions such as juvenile idiopathic arthritis, ALS, and chronic kidney disease, with existing companies utilising a range of modalities.
External link for NG Bio
London, GB
NG Bio reposted this
For those of you who have had to listen to me for the last 4 years go on (and on) about why we need to focus on #autoimmunediseases and #inflammation, in one of their latest episodes, STAT proves that I'm not going mad. It highlights why now and some of the challenges patients with autoimmune diseases are facing. It is a complex equation for patients but we shouldn’t shy away from it. Relevant times: 3 mins to 9 mins https://lnkd.in/e_HfzH-6
We're excited to announce our latest investment in Mesenbio, a biotech company born out of the University of York. Mesenbio has successfully raised £1.4 million in funding in an investment round co-led by DSW Ventures and NG Bio, including grant funding from Innovate UK as well as investment from NG Bio’s angel investors. Mesenbio is developing arthritis therapies using stem cell-engineered extracellular vesicles (EVs). These EVs offer anti-inflammatory and regenerative benefits, reducing joint inflammation whilst aiding in tissue repair. Congratulations to Professor Paul Genever and Dr. David Kuntin. At NG Bio, we're committed to investing in breakthrough cures for chronic diseases. For more information about Mesenbio, or to discover other transformative therapies, contact Jason Goldstein at j.goldstein@ngbio.co.uk. Stay tuned for more updates on this exciting journey! Find the press releases on our website: https://lnkd.in/gUUVpsza #BiotechInvestment #Innovation #Healthcare #Mesenbio #ArthritisTreatment #StemCellResearch #ClinicalTrials #TransformingLives